Peter O'Neill

Statistics

Publications

Citations

H-Index

Active since

2012

Affiliations

Tower Cancer Research Foundation(Current)

University of Michigan

Newland Medical Associates

University of Iowa

Incyte (United States)

Peter O'Neill is an author at Tower Cancer Research Foundation specializing in hematologic toxicity, hematology, and hematologic adverse event monitoring.

Publications per year

2012–2012

Publications

Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts

Moshe Talpaz, Ronald Paquette, Lawrence B. Afrin et al. · Blood · 2012 · 14 citations

Medicine, Hematology, Pharmacology +12

Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50–100x10<sup>9</sup>/L.

Moshe Talpaz, Solomon I. Hamburg, Katarzyna Jamieson et al. · Journal of Clinical Oncology · 2012 · 11 citations

Medicine, Hematology, Pharmacology +8

1–2 of 2